Impact of cancer cachexia progression on CYP3A4 and OATP1B activity: Quantitative analysis using endogenous biomarker

Impact of cancer cachexia progression on CYP3A4 and OATP1B activity: Quantitative analysis using endogenous biomarker - Impact of cancer cachexia progression on CYP3A4 and OATP1B activity: Quantitative analysis using endogenous biomarker

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000044390

Enrollment

120

Registered

2021-06-01

Start date

2020-06-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cancer Cachexia

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients who can be evaluated for the progression of cancer cachexia.

Exclusion criteria

Exclusion criteria: Patients who are concomitantly using drugs that induce or inhibit CYP3A and OATP1B. Patients with hepatic/renal dysfunction.

Design outcomes

Primary

Measure	Time frame
Evaluation of the effect of cancer cachexia progression on CYP3A4 and OATP1B activity	—

Secondary

Measure	Time frame
1) Relationship between cancer cachexia progression and plasma concentration, the endogenous substrate for CYP3A4. 2) Relationship between cancer cachexia progression and plasma concentration, the endogenous substrate for OATP1B. 3) Relationship between plasma concentration of the endogenous substrate and inflammatory cytokine concentration. 4) Relationship between plasma concentration of the endogenous substrate and inflammatory cytokine concentration. 5) Relationship between Phenotype of CYP3A5 gene polymorphism and plasma concentration of the endogenous substrate, various inflammatory cytokine concentrations, and cancer cachexia progression. 6) Relationship between Phenotype of OATP1B gene polymorphism and plasma concentration of the endogenous substrate, various inflammatory cytokine concentrations, and cancer cachexia progression.	—

Measure

Time frame

1) Relationship between cancer cachexia progression and plasma concentration, the endogenous substrate for CYP3A4. 2) Relationship between cancer cachexia progression and plasma concentration, the endogenous substrate for OATP1B. 3) Relationship between plasma concentration of the endogenous substrate and inflammatory cytokine concentration. 4) Relationship between plasma concentration of the endogenous substrate and inflammatory cytokine concentration. 5) Relationship between Phenotype of CYP3A5 gene polymorphism and plasma concentration of the endogenous substrate, various inflammatory cytokine concentrations, and cancer cachexia progression. 6) Relationship between Phenotype of OATP1B gene polymorphism and plasma concentration of the endogenous substrate, various inflammatory cytokine concentrations, and cancer cachexia progression.

—

Countries

Japan

Contacts

Public ContactTakahiro Sumimoto

Oita University Hospital Clinical pharmacy

sumimoto@oita-u.ac.jp0975866112

Outcome results